Holen Sie sich die Stockscreener-App
3.02
0.67%
0.02
Handel nachbörslich:
3.02
Schlusskurs vom Vortag:
$3.00
Offen:
$3
24-Stunden-Volumen:
60,120
Relative Volume:
1.26
Marktkapitalisierung:
$26.58M
Einnahmen:
$442.00K
Nettoeinkommen (Verlust:
$-30.46M
KGV:
-0.6771
EPS:
-4.46
Netto-Cashflow:
$-27.47M
1W Leistung:
-1.95%
1M Leistung:
-27.05%
6M Leistung:
-47.11%
1J Leistung:
-56.76%
1-Tages-Spanne:
$2.8964
$3.08
1-Wochen-Bereich:
$2.76
$3.18
52-Wochen-Spanne:
$2.57
$9.20
Clene Inc Stock (CLNN) Company Profile
Firmenname
Clene Inc
Sektor
Branche
Telefon
801-676-9695
Adresse
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Vergleichen Sie CLNN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
3.02 | 26.58M | 442.00K | -30.46M | -27.47M | -4.46 |
|
KHC
Kraft Heinz Co
|
29.94 | 36.36B | 25.85B | 2.74B | 3.02B | 2.26 |
|
GIS
General Mills Inc
|
57.67 | 32.31B | 19.64B | 2.56B | 2.48B | 4.55 |
|
K
Kellanova
|
82.41 | 28.46B | 12.75B | 1.34B | 1.13B | 3.87 |
|
MKC
Mccormick Co Inc
|
74.67 | 20.81B | 6.68B | 792.60M | 774.40M | 2.94 |
|
HRL
Hormel Foods Corp
|
30.40 | 16.80B | 11.92B | 805.04M | 1.01B | 1.46 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-10-04 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-07-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-05-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-09-28 | Eingeleitet | Oppenheimer | Outperform |
Clene Inc Aktie (CLNN) Neueste Nachrichten
Clene to Present at the Emerging Growth Conference | CLNN Stock News - GuruFocus
Nanomedicines Market to Witness Massive Growth by 2032 | Abbott - openPR.com
Clene to Present at the Emerging Growth Conference - Bluefield Daily Telegraph
Clene Unveils Latest ALS and MS Treatment Progress: Key Presentation Coming - Stock Titan
Clene’s (CLNN) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Nanomedicines Market Generated Opportunities, Future Scope 2025-2032 | Abbott, CombiMatrix, Clene Nanomedicine - newstrail.com
Clene’s (CLNN) Buy Rating Reiterated at HC Wainwright - Defense World
Clene reports MS patient improvements with CNM-Au8 treatment By Investing.com - Investing.com India
Clene announces evidence of remyelination, neuronal repair with CNM-Au8 - TipRanks
Clene reports MS patient improvements with CNM-Au8 treatment - Investing.com Australia
Breakthrough: New MS Drug Actually Repairs Brain Damage, Trial Data Shows 90% Success Rate - Stock Titan
Clene (NASDAQ: CLNN) to Present at Jones Healthcare and Technology Innovation Conference - The Globe and Mail
CLNN stock touches 52-week low at $2.95 amid market challenges By Investing.com - Investing.com South Africa
CLNN stock touches 52-week low at $2.95 amid market challenges - Investing.com India
Clene to Present at the Jones Healthcare and Technology Innovation Conference - The Manila Times
Clene Reveals Latest ALS and MS Treatment Innovations at Major Healthcare Conference - Stock Titan
Promising Nanotechnology Stocks To ResearchMarch 29th - MarketBeat
Roth Capital Has Negative Estimate for Clene Q1 Earnings - Defense World
Clene Inc. settles debt with equity issuance - Investing.com
Roth Capital Has Optimistic Outlook of Clene FY2027 Earnings - Defense World
Clene Inc.'S (NASDAQ: CLNN) Q1 Virtual Investor Summit Presentation Available For On-Demand Viewing - MENAFN.COM
Research Analysts Issue Forecasts for Clene Q1 Earnings - Defense World
What is HC Wainwright’s Estimate for Clene FY2028 Earnings? - Defense World
Clene stock touches 52-week low at $3.8 amid market challenges - Investing.com Australia
Clene stock touches 52-week low at $3.8 amid market challenges By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $31 target on Clene stock post-results By Investing.com - Investing.com Canada
Clene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025 - StreetInsider.com
H.C. Wainwright maintains $31 target on Clene stock post-results - Investing.com
Clene (NASDAQ:CLNN) Given “Buy” Rating at HC Wainwright - Defense World
Clene’s (CLNN) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Clene Inc. Reports 2024 Financial Results and Strategic Plans - TipRanks
Clene Inc (CLNN) Reports Q4 EPS of -$5.67, Revenue of $0.36M, Mi - GuruFocus
Clene Inc. Files For Mixed Shelf Of Up To $160 MillionSEC Filing -March 24, 2025 at 04:51 pm EDT - MarketScreener
Clene (NASDAQ: CLNN) Plans 2025 NDA Submission Following Positive ALS Trial Data - Barchart.com
Clene Inc. reports results for the quarter ended December 31Earnings Summary - TradingView
Clene Inc. (CLNN) Reports Q4 Loss, Lags Revenue Estimates - MSN
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights - The Manila Times
Breakthrough: Clene's ALS Treatment Shows 11.9-Month Survival Benefit in Severe Cases - Stock Titan
BiomednewsbreaksClene Inc. (NASDAQ: CLNN) Unveils Progress On CNM-Au8(R), Eyes Potential Fast-Track FDA Approval - MENAFN.COM
Bullish Clene Insiders Loaded Up On US$583.4k Of Stock - Yahoo
Clene Inc. shareholder general resonance sells $12,091 in stock By Investing.com - Investing.com India
Clene Inc. shareholder general resonance sells $12,091 in stock - Investing.com
Dually-Listed Aerospace Stock Finds Premarket Success Following Key Announcement - The Globe and Mail
Top Nanotechnology Stocks To ConsiderMarch 15th - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Clene (NASDAQ:CLNN) - Defense World
D. Boral Capital Reaffirms Buy Rating for Clene (NASDAQ:CLNN) - Defense World
H.C. Wainwright maintains Clene stock Buy rating, $31 target - Investing.com India
Finanzdaten der Clene Inc-Aktie (CLNN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Clene Inc-Aktie (CLNN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| General Resonance LLC | 10% Owner |
Mar 18 '25 |
Sale |
4.45 |
1,333 |
5,932 |
712,252 |
| MATLIN DAVID J | Director |
Sep 30 '24 |
Buy |
4.75 |
92,307 |
438,458 |
444,491 |
| Mortenson Mark | Chief Science Officer |
Sep 30 '24 |
Buy |
4.75 |
20,512 |
97,432 |
28,949 |
| Etherington Robert Dee | Chief Executive Officer |
Sep 30 '24 |
Buy |
4.75 |
10,000 |
47,500 |
40,149 |
| Etherington Robert Dee | Chief Executive Officer |
Jul 29 '24 |
Option Exercise |
3.00 |
27,320 |
81,960 |
30,149 |
| General Resonance LLC | 10% Owner |
Apr 30 '24 |
Sale |
0.42 |
13,000 |
5,416 |
15,326,712 |
| General Resonance LLC | 10% Owner |
May 01 '24 |
Sale |
0.40 |
13,000 |
5,148 |
15,313,712 |
| General Resonance LLC | 10% Owner |
Apr 24 '24 |
Sale |
0.33 |
10,000 |
3,278 |
15,349,712 |
2.88%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):